PE20010027A1 - Uso de interferon alfa pegilado en pacientes con melanoma - Google Patents

Uso de interferon alfa pegilado en pacientes con melanoma

Info

Publication number
PE20010027A1
PE20010027A1 PE2000000310A PE0003102000A PE20010027A1 PE 20010027 A1 PE20010027 A1 PE 20010027A1 PE 2000000310 A PE2000000310 A PE 2000000310A PE 0003102000 A PE0003102000 A PE 0003102000A PE 20010027 A1 PE20010027 A1 PE 20010027A1
Authority
PE
Peru
Prior art keywords
melanoma
sticked
patients
alpha interferon
patient
Prior art date
Application number
PE2000000310A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010027A1 publication Critical patent/PE20010027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

SE REFIERE AL USO DE INTERFERON ALFA 2a O 2b PEGILADO UTIL PARA EL TRATAMIENTO DE MELANOMA (MELANOMA CUTANEO) EN UN PACIENTE CON MELANOMA QUE HA SIDO QUIRURGICAMENTE REMOVIDO; O EN UN PACIENTE NUEVO; O A UN PACIENTE AL QUE SE LE HA DIAGNOSTICADO RECIENTEMENTE MELANOMA; O HA EXPERIMENTADO TRATAMIENTO O ES INTOLERANTE O RESISTENTE AL INTERFERON ALFA; UTILIZANDOSE 3µg/Kg A 9 µg/Kg UNA VEZ POR SEMANA POR UN PERIODO DE POR LO MENOS 24 MESES; PARA INCREMENTAR EL TIEMPO DE SUPERVIVENCIA LIBRE DE PROGRESION
PE2000000310A 1999-04-08 2000-04-06 Uso de interferon alfa pegilado en pacientes con melanoma PE20010027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
PE20010027A1 true PE20010027A1 (es) 2001-02-05

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000310A PE20010027A1 (es) 1999-04-08 2000-04-06 Uso de interferon alfa pegilado en pacientes con melanoma

Country Status (22)

Country Link
EP (3) EP1043026B1 (es)
JP (1) JP2000319195A (es)
CN (1) CN1390132A (es)
AR (1) AR023398A1 (es)
AT (3) ATE496631T1 (es)
AU (1) AU771569B2 (es)
BR (1) BR0009646A (es)
CA (1) CA2303992A1 (es)
CO (1) CO5170404A1 (es)
CY (1) CY1108922T1 (es)
DE (3) DE60041290D1 (es)
DK (2) DK1043026T3 (es)
ES (2) ES2319776T3 (es)
HK (2) HK1032349A1 (es)
HU (1) HU230057B1 (es)
MY (1) MY126763A (es)
NO (1) NO328111B1 (es)
PE (1) PE20010027A1 (es)
PT (2) PT1535622E (es)
TW (1) TWI292320B (es)
WO (1) WO2000061175A2 (es)
ZA (1) ZA200108173B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
AR023398A1 (es) 2002-09-04
BR0009646A (pt) 2002-02-05
CA2303992A1 (en) 2000-10-08
EP1043026A2 (en) 2000-10-11
EP2025344A1 (en) 2009-02-18
EP2025344B1 (en) 2011-01-26
EP1535622A1 (en) 2005-06-01
CN1390132A (zh) 2003-01-08
AU771569B2 (en) 2004-03-25
AU4204600A (en) 2000-11-14
DK1043026T3 (da) 2005-07-04
DK1535622T3 (da) 2009-04-20
CO5170404A1 (es) 2002-06-27
DE60020444T2 (de) 2006-05-04
DE60045591D1 (de) 2011-03-10
JP2000319195A (ja) 2000-11-21
ES2239954T3 (es) 2005-10-16
NO20014852D0 (no) 2001-10-05
HU230057B1 (hu) 2015-06-29
ATE496631T1 (de) 2011-02-15
DE60041290D1 (de) 2009-02-12
PT1535622E (pt) 2009-03-19
ES2319776T3 (es) 2009-05-12
ATE296639T1 (de) 2005-06-15
HK1075416A1 (en) 2005-12-16
HUP0200775A3 (en) 2002-09-30
EP1535622B1 (en) 2008-12-31
EP1043026A3 (en) 2000-12-20
MY126763A (en) 2006-10-31
ATE419001T1 (de) 2009-01-15
DE60020444D1 (de) 2005-07-07
WO2000061175A2 (en) 2000-10-19
ZA200108173B (en) 2003-01-06
TWI292320B (en) 2008-01-11
EP1043026B1 (en) 2005-06-01
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
PT1043026E (pt) 2005-09-30
WO2000061175A3 (en) 2001-02-01
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
HK1032349A1 (en) 2001-07-20

Similar Documents

Publication Publication Date Title
MY144318A (en) Methods of treating hiv infection.
ES2172288T3 (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
AU6473601A (en) Gabapentin analogues for sleep disorders
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
SE9400935L (sv) Tandarrangemang
ZA941525B (en) Use of riluzole in the treatment of nero-AIDS
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
IL150286A0 (en) Treatment of dna viral infections
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
PE20010027A1 (es) Uso de interferon alfa pegilado en pacientes con melanoma
BRPI0608326A2 (pt) suporte de exoesqueleto para colocação de uma fita de tratamento dental
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
PE20010026A1 (es) Composicion que comprende interferon alfa pegilado
ES2178650T3 (es) Uso de terbinafina para el tratamiento terapeutico de neumocitosis.
GB9802542D0 (en) New use
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
FR2669821B1 (es)
ES2166778T3 (es) Factor de crecimiento ii de tipo insulina como agente antitumoral.
ES2083874T3 (es) (amino-3 fenil)-1 etanosulfonato de hidroquinina opticamente activo, su preparacion y su utilizacion.
HU9500708D0 (en) Optically active alkylammonium(amino-3phenyl)-1ethanesulfonate derivatives, preparation and use thereof
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
UA40698A (uk) Спосіб фіксації бюгельних протезів

Legal Events

Date Code Title Description
FC Refusal